COMMUNIQUÉS West-GlobeNewswire

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
10/12/2025
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat [...]
Veru to Report Fiscal Year 2025 Financial Results on December 17th
10/12/2025
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
10/12/2025
Platform Poised to Expand into Joint and Cartilage Repair HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with [...]
Commure Partners with Val Verde Regional Medical Center to Enhance Clinical Workflows with MEDITECH-Integrated Ambient AI
10/12/2025
Community-Based Hospital Pioneers Rural Healthcare Adoption of Advanced AI Technology to Improve Clinician Experience and Patient Access MOUNTAIN VIEW, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Commure , a leading [...]
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
10/12/2025
TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
10/12/2025
THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity [...]
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
10/12/2025
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or [...]
Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
10/12/2025
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic’s granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company [...]
OneMedNet Reports Strong Momentum and Industry Excitement at RSNA
10/12/2025
MINNEAPOLIS, Dec. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network, today [...]
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
10/12/2025
Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “ [...]
Aeroflow Health and Molina Healthcare Break Down Barriers to Nutrition and Diabetes Care in South Carolina
10/12/2025
The new partnership expands nutrition counseling and DSME services for Molina Commercial and Medicare members statewide to support long-term health outcomes ASHEVILLE, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Aeroflow [...]
Branded Legacy, Inc. Announces Complete Management Overhaul and Strategic Reset Under New Leadership
10/12/2025
VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG ) ("the Company") today announced a comprehensive restructuring and change of control following the acquisition [...]
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
10/12/2025
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri [...]
USOSM Surgeon Partners Gave 2,170+ Patients in Africa and Central America More Reasons to Smile through Medical Missions This Year
10/12/2025
IRVING, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- During the past 12 months, U.S. Oral Surgery Management ( USOSM ) surgeon partners and their teams provided free oral care to more than 2,170 patients in Tanzania, Belize [...]
4D Path Collaborates with AMD and Oracle to Scale Predictive Oncology
10/12/2025
Physics-informed, deterministic biomarkers from routine H&E slides run natively on AMD EPYC™ CPUs — enabling reproducible AI-driven solution in clinical trials SUNNYVALE, Calif. and NEWTON, Mass., Dec. 10, 2025 ( [...]
Akira Botanicals Announces Farm-Direct, Compliant CBD Relief Oils and Salves as Federal Hemp Rules Shift
10/12/2025
Akira Botanicals highlights its seed-to-bottle production model and its Sleep Oil with CBN, Energy Oil with THCV, and Relief Salves as the hemp industry adapts to new federal requirements. Marshall, NC, Dec. 10, 2025 ( [...]
JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
10/12/2025
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years. PPF is a rare lung condition, more life-threatening than many forms of cancer, [...]
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
10/12/2025
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce [...]
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC
10/12/2025
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFR TM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor [...]

Pages